In this study, we examined the impact of dexmedetomidine (DEX) on the effectiveness of epidural analgesia and labor outcomes. We administered different doses of DEX combined with 0.1% ropivacaine for epidural analgesia to evaluate their clinical effects and safety. To assess the effects of different concentrations of DEX in parturient women receiving epidural analgesia, we conducted a randomized double‐blind trial. We selected 400 parturient women and randomly assigned them to four groups, with 100 parturient women in each group: S0.1 (0.1μg/ml DEX), S0.2 (0.2μg/ml DEX), S0.3 (0.3μg/ml DEX), and a control group (0.3μg/ml sufentanil). Post‐analgesia, we recorded the bromage scores, labor duration, method of delivery, bleeding, neonatal Apgar scores, adverse reactions, and maternal satisfaction. The number of patients with Bromage score ≥ 2 and the incidence of bradycardia were higher in the S0.3 group compared to the other three groups (P < 0.05), while the high satisfaction rate was lower in the S0.3 group (P < 0.05). Moreover, we found that the number of times additional patient‐controlled analgesia was administered was higher in the S0.1 group compared to the remaining three groups (P < 0.05). The control group exhibited a higher incidence of pruritus than the other three groups (P < 0.05). In conclusion, for labor pain relief during spinal anesthesia, epidural analgesia with 0.1% ropivacaine combined with 0.2 μg/ml DEX provides relatively ideal analgesic effects, higher maternal satisfaction, and reduces the incidence of pruritus compared to the combination of 0.1% ropivacaine and 0.3 μg/mL sufentanil.This article is protected by copyright. All rights reserved